Marinus Pharmaceuticals, Inc. (MRNS)
Largest Insider Buys in Sector
MRNS Stock Price History Chart
MRNS Stock Performance
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for …
Insider Activity of Marinus Pharmaceuticals, Inc.
Over the last 12 months, insiders at Marinus Pharmaceuticals, Inc. have bought $0 and sold $248,297 worth of Marinus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Marinus Pharmaceuticals, Inc. have bought $125,000 and sold $304,264 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $125,000 was made by Braunstein Scott (Chief Executive Officer) on 2019‑12‑13.
List of Insider Buy and Sell Transactions, Marinus Pharmaceuticals, Inc.
| 2024-08-05 | Sale | CHAIRMAN AND CEO | 12,145 0.0227% | $1.13 | $13,724 | +33.64% | ||
| 2024-08-05 | Sale | CFO AND COO | 4,657 0.0087% | $1.13 | $5,262 | +33.64% | ||
| 2024-08-05 | Sale | CHIEF MEDICAL OFFICER | 4,828 0.009% | $1.13 | $5,456 | +33.64% | ||
| 2024-08-05 | Sale | CHIEF COMMERCIAL OFFICER | 3,820 0.0072% | $1.14 | $4,355 | +33.64% | ||
| 2024-08-05 | Sale | SVP, GEN. COUNSEL & CORP. SEC. | 3,621 0.0068% | $1.13 | $4,092 | +33.64% | ||
| 2024-02-20 | Sale | CHIEF COMMERCIAL OFFICER | 2,153 0.004% | $9.56 | $20,583 | -84.49% | ||
| 2024-02-20 | Sale | SVP, GEN. COUNSEL & CORP. SEC. | 1,894 0.0035% | $9.57 | $18,126 | -84.49% | ||
| 2024-02-16 | Sale | CHAIRMAN AND CEO | 11,850 0.0217% | $9.94 | $117,789 | -85.14% | ||
| 2024-02-16 | Sale | CFO AND COO | 3,092 0.0057% | $9.97 | $30,827 | -85.14% | ||
| 2024-02-16 | Sale | CHIEF MEDICAL OFFICER | 2,814 0.0052% | $9.98 | $28,084 | -85.14% | ||
| 2023-08-08 | Sale | CHAIRMAN AND CEO | 30 <0.0001% | $8.94 | $268 | -20.88% | ||
| 2023-08-08 | Sale | CFO AND COO | 14 <0.0001% | $8.93 | $125 | -20.88% | ||
| 2023-08-08 | Sale | CHIEF MEDICAL OFFICER | 13 <0.0001% | $8.93 | $116 | -20.88% | ||
| 2023-08-08 | Sale | CHIEF COMMERCIAL OFFICER | 11 <0.0001% | $8.93 | $98 | -20.88% | ||
| 2023-08-08 | Sale | SVP, GEN. COUNSEL & CORP. SEC. | 11 <0.0001% | $8.93 | $98 | -20.88% | ||
| 2023-08-07 | Sale | CHAIRMAN AND CEO | 6,413 0.0133% | $9.55 | $61,244 | -22.45% | ||
| 2023-08-07 | Sale | CFO AND COO | 2,790 0.0058% | $9.54 | $26,617 | -22.45% | ||
| 2023-08-07 | Sale | CHIEF MEDICAL OFFICER | 2,889 0.006% | $9.55 | $27,590 | -22.45% | ||
| 2023-08-07 | Sale | CHIEF COMMERCIAL OFFICER | 2,385 0.0049% | $9.52 | $22,705 | -22.45% | ||
| 2023-08-07 | Sale | SVP, GEN. COUNSEL & CORP. SEC. | 2,169 0.0045% | $9.54 | $20,692 | -22.45% |
Insider Historical Profitability
| Braunstein Scott | CHAIRMAN AND CEO | 298667 0.5422% | $0.34 | 1 | 4 | +38.89% |
| Domain Partners VI, L.P. | 10 percent owner | 2476886 4.4966% | $0.34 | 1 | 0 | +9.89% |
| Bloch Stephen M | director | 2461398 4.4684% | $0.34 | 1 | 0 | +9.89% |
| Canaan VII LP | 10 percent owner | 1850783 3.3599% | $0.34 | 1 | 9 | +9.89% |
| Cashman Christopher Michael | CEO | 239761 0.4353% | $0.34 | 1 | 2 |
Institutional Investor Ownership
| Suvretta Capital Management, LLC | $46.18M | 9.3 | 5.11M | -4.44% | -$2.15M | 1.95 | |
| BlackRock | $42.67M | 8.59 | 4.72M | +2.64% | +$1.1M | <0.01 | |
| Avoro Capital Advisors Llc | $37.43M | 7.54 | 4.14M | +31.45% | +$8.96M | 0.45 | |
| Franklin Templeton Investments | $31.58M | 6.36 | 3.49M | -8.89% | -$3.08M | 0.01 | |
| Cormorant Asset Management Lp | $29.38M | 5.92 | 3.25M | 0% | +$0 | 1.37 |